Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I follow this web site also http://regsho.finra.org/regsho-March.html, but although I see a large percentage of shorts relative to overall trades I never see a short squeeze generated. That leads me to believe they are covering quickly on high volume days
CARLSBAD, Calif. – December 30, 2008— Robert Brehm, CEO of Green Mountain Development Corp, (Pinksheet: GMND), an incubator of green technology companies, announced today that the company has obtained a license to manufacture, distribute and use microbial technology for organic sustainable agricultural applications. In a concurrent transaction, the company became independent by purchasing all of the voting control stock of GMND from U.S. Microbics, Inc. (Pinksheet: BUGS), its parent company. Both transactions were undertaken to strengthen the financial position of the company and prepare for future funding and agricultural product sales.
http://www.greenbizness.com/news
I question whether these 2 companies are related at all anymore.
outside of the licensing agreements
I don't remember this stock ever being worth 30 cents are you sure you are not talking about BUGS
you are right. I accumulate every chance I get.
P.S. I think this has real long run potential
HA HA HA you are brutally funny
look at green mountain board post 717 and you will see where the shelters went LOL
here is a passage from FINRA. org with the applicable link. It appears to me that they are actual short sales applicable to that particular date.
"Daily Short Sale Volume File
The Daily Short Sale Volume File will provide daily access to the aggregate volume of
short sales in NMS Stocks and OTC Equity Securities reported to a consolidated tape and
traded over-the-counter during regular trading hours on each trading day. FINRA will
post the Daily Short Sale Volume File within a reasonable amount of time after the end
of regular trading hours on each trading day. Specifically, the Daily Short Sale Volume
File will include the following:
trade date;
trading symbol;
aggregate reported share volume of executed short sale trades during regular
trading hours;
aggregate reported share volume of all executed trades during regular trading
hours; and
market identifier."
http://www.finra.org/web/groups/industry/@ip/@reg/@notice/documents/notices/p120044.pdf
I called FINRA and asked about the numbers. They are "SHORTS" not Failure to deliver
I think the future is bright also. I saw where they had granted a number of option to the officers with a .015 or .018 strike price and a 2012 maturity date
Pluristem Therapeutics Inc. (NASDAQ:PSTI) is the 9th best-performing stock year-to-date in this segment of the market. It has risen 60.14% since the beginning of this year. Its price percentage change is 102.65% for the last 52 weeks.
http://www.cnanalyst.com/2011/03/top-10-best-performing-biotech-stocks-year-to-date-rprx-tthi-gene-clda-dusa-vtus-anik-icgn-psti-tsrx.html
Date|Symbol|ShortVolume|ShortExemptVolume|TotalVolume|Market
20110316|OTOW|1560550|0|5789867|O
this is the amount of short volume for yesterdays trading.
approximately 27% short sales.
data source http://regsho.finra.org/FORFshvol20110316.txt
http://nothingbutbuzz.com/micro-cap-stock-superconductor-technologies-inc-nasdaqscon/863777/
Superconductor Technologies, Inc. (NASDAQ:SCON) jumped 49.59% or $1.21 in last 1 month trading sessions from $2.44 on Feb 8 to $3.65 on March 8.
The Company announced that it intends to release its fourth quarter and year end 2010 financial results before the market opens on Thursday, March 10, 2011.
The Company announced on Feb 16, that it had received acceptance from a key potential customer for its second generation (2G) HTS wire sample. It stated that the 2G HTS wire sample met this customer’s requirements for current carrying performance at the specified temperature and magnetic field strength necessary for applications involving large rotating machines. This announcement of product validation by a specific potential customer completes another major step in the company’s commercialization path.
Following the announcement made on Feb 1 of the successful production of 2G HTS wire samples meeting the desired power transmission requirements specified by potential customers in three distinct markets (AC power transmission cable, Superconducting Fault Current Limiters (SFCLs) and wind turbine generators), the company on Feb 9, announced independent verification of the wire’s unprecedented in-field electrical current-carrying performance.
The independent testing of the company’s HTS wire was conducted at the Superconductor Technology Center at Los Alamos National Laboratory (LANL) and the published results indicate a breakthrough achievement in current capacity performance never before attained at the temperature of 65 Kelvin and within the specified magnetic fields ratings (Tesla rating) for superconductor fault current limiters, wind turbine generators, transmission wire for smart grid and industrial motors applications.
The Stock is currently trading at $3.65, 6 cents below the previous day close of $3.71. Volume of 1.24 million shares has been trade compared to the daily average of 1.41 million shares. The market capitalization of the stock stands at $99.34 million with beta of 2.62. The stock has 52 week range of $1.30-$4.19. Currently, the stock is trading above its 50 day & 200 day moving average of $2.58 & $1.85 respectively. It jumped 143.33% in last 3 month.
Superconductor Technologies Inc. is engaged in the research, development, manufacture and marketing of infrastructure products for wireless voice and data applications.
http://www.zacks.com/research/get_news.php?id=068l1206
Mar 09, 2011 (SmarTrend(R) News Watch via COMTEX) -- Below are the bottom five companies in the Specialty Chemicals industry ranked by Revenue Per Employee (RPE). Analysts use RPE as a measure to compare the productivity of companies in the same industry.
Altair Nanotechnologies (NASDAQ:ALTI) ranks first with an RPE of $79K; Zoltek (NASDAQ:ZOLT) ranks second with an RPE of $117K; and Nanophase Technologies (NASDAQ:NANX) ranks third with an RPE of $214K.
for what it is worth:
Industrial Nanotech Inc. (PINK:INTK) is another company that saw its volume surge more than 100% as the stock climbed to $0.0370 with a relative strength index of 70.17, which is again considered to be in an overbought territory. The stock has penetrated its 50 day moving average of $0.0285 and its 200 day moving average of $0.0241 with an extreme bullish momentum.
http://www.smallcapnetwork.com/Risk-and-Reward-Ratio-Is-an-Upward-Sloping-Line-CFW-INTK-BLLN/s/article/view/p/mid/2/id/413/
Equities research analysts at MDB Research upgraded shares of Altair Nanotechnologies, Inc. (NASDAQ: ALTI) to a “buy” rating in a research note to investors on Wednesday. The analysts currently have a $3.50 price target on the stock, up from $3.20.
Separately, analysts at Zacks Investment Research reiterated a “neutral” rating on shares of Altair Nanotechnologies, Inc. in a research note to investors on Thursday, December 30th.
Altair Nanotechnologies Inc. is engaged in the business of developing, manufacturing and selling its nano lithium titanate battery products and providing related design, installation and test services. The Company’s primary focus is marketing its large-scale energy storage solutions to power companies and electric grid operators throughout the world. In addition, it also markets its battery products to the electric and hybrid-electric mass-transit markets. It also provides contract research services on select projects where it can utilize its resources to develop intellectual property and/or new products and technology. The Company is organized into two divisions: Power and Energy Group and all other division.
http://www.americanbankingnews.com/2011/03/03/altair-nanotechnologies-inc-alti-upgraded-by-mdb-research-to-buy/
I recently attended an investor presentation by Mesoblast. It is a fine company and their technology has been validated by a 130 million dollar upfront payment from Cephalon and an additional equity investment by Cephalon of about 107 million dollars. The deal also involves a possible 1.5 billion dollars in clinical milestones for three indications that Cephalon has licensed and Cephalon will be paying all of the clinical trial costs in these indications.
After the presentation I am more convinced than ever that Pluristem Therapeutics (Nasdaq: PSTI) is tremendously undervalued. Mesoblast's market capitalization is over 1.8 billion dollars compared to Pluristem's valuation of about 100 million dollars.
PLURISTEM THERA
2.29 - (0.00%)
Intraday | 3 Month | 6 Month | 1 Year
The last time I wrote about Pluristem they were a company that had just gotten approval to run a pivotal trial in the indication of Critical Limb Ischemia by both the FDA and EMA. They had one problem, they only had a few million dollars in the bank. Since that time the company has raised over 40 million dollars from warrant exercises and an equity raise, priced at $3.25. Based on their financial position the company is a better value today than it was back in February. They are one of the few biotech companies in the enviable position of having 3 to 4 years of cash.
Mesoblast's technology platform is all about adult mesenchymal precursor cells. About one out of every 100,000 cells removed from a healthy volunteer's bone marrow, not a pleasant experience, will be the cell used in their studies and commercialization process. Pluristem gets their mesenchymol like stromal cells from the placenta which is considered a medical waste and very easy to get access to.
Both companies claim that their cells are extremely potent with no immune reactions. The cells also avoid the ethical and safety issues of embryonic stem cells, and are backed by strong intellectual property protection. Both companies have off the shelf products, claim batch to batch consistency and say their cells can be expanded in large numbers without affecting potency. These are terrific assets because this means a low cost of goods with no supply constraints on approval making both technologies perfect for large pharma because they will have drug like properties and high margin products. The mechanism of action of each of the company’s products is immune modulation as opposed to most stem cells that work by cell differentiation. In fact in animal models within sixty days of delivery of cells you can no longer find the cells in the tissue where the cells were delivered. The companies haven't done this in humans because you can't take biopsies of these areas in humans.
As I said earlier both companies say their drugs are non-immunogenic. As far as I am concerned Pluristem has done more to prove this. Mesoblast has never given more than one injection to any one individual. In Pluristem's trial in Critical Limb Ischemia they gave repeat doses from the same placenta two weeks after the initial dose to many of their patients in an effort to exhibit that their cells do not have an immunogenicity issue. So far so good. There were no problems. In fact in their upcoming phase three trial a dose four months after the first injection is part of the protocol and it is believed this should help the efficacy of the stem cell treatment to increase the length of treatment effect.
Mesoblast said in their presentation that if their drug were to receive approval their contract manufacturer, would have to build a bricks and mortar facility in a tax advantaged area like Singapore to produce their product in a commercial scale. This is a concern to me because even if their pivotal trial is acceptable this could be an issue with the FDA. Many drug approvals are held up because of issues with the CMC section of the drug approval process. In this case the FDA might have an issue with the fact that the drug produced for the phase 3 study would be produced at a different manufacturing facility with a different cell bank, than what will be used in the manufacturing of the commercial facility. Pluristem in contrast is doing a very intelligent thing. They are manufacturing their clinical trial batches in the same facility and bioreactor that they will be using for the commercial launch of the drug, if they have a successful clinical trial. This is an incredibly important fact that I do not think most people following the companies have realized.
If you put these things together I think Pluristem has some advantages to Mesoblast but even if you say the products are the same or the differences are immaterial the Pluristem market value comparison to that of Mesoblast just doesn't make any sense and we should see a rise in Pluristem's valuation to fill that gap. I also have to believe that because of the simplicity and intellectual property around Pluristem's manufacturing it will not be long before "big pharma" takes a serious look at Pluristem and one of those companies commits to a similar licensing deal with Pluristem, that Cephalon offered to, and was accepted by Mesoblast.
MSB’s market value is currently approximately $1.8 Billion while PSTI’s market value is approximately $100-120 Million. As PSTI enters clinical trials for the other indications with their proprietary placental-expanded (PLX) cells, and for the reasons I point out in this report, their market value should reasonably approach or potentially the market value of MSB. Ergo, my opinion to aggressively accumulate PSTI’s Stock.
http://biomedreports.com/2011030864793/a-tale-of-two-stem-cell-platforms-a-discussion-of-mesoblast-and-pluristem.html
I bought this stock in the late 90's. It went fron 10 to 120.00. It is speculative but I like the technology. I think super cooling/super conductivity will eventually have a lot of uses, if you are willing to wait
I think the relationship between bugs and gmnd is far from clear. I fear brehm is cannibalizing bugs to capitalize his new firm. Leaving the bugs shareholders high and dry. I find it interesting that there is little chatter on either board given the increase in PPS for gmnd
your guess ia as good as mine. The relation ship between all these companies is unclear to me.
best of luck
apparently there has been an avenue of communication open with mr. brehm since january.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=60474971
one might question the motives involved here
has anyone been able to trade this stock. Fidelity says that the symbol is invalid
Altair Nanotechnologies Inc. (Altairnano) (NASDAQ: ALTI) today announced it had been selected by MDB Capital Group as one of the 2011 "Best and Brightest" innovating companies with market capitalization less than $500 million. The award recognizes companies with leading intellectual property based upon MDB's proprietary PATENTVEST metrics.
Christopher Marlett, CEO of MDB Capital Group, commented by saying, "Altairnano's imbedded IP value and demonstrated innovation places it in the top 10% of the approximately 1500 technology companies trading below $500MM in market value as ranked by our proprietary IP intelligence database called PatentVest. Our research has shown that this elite group of companies demonstrating above average PatentVest metrics, such as PatentVest Tech Score and the compound annual growth rate (CAGR) of patent applications, have significantly outperformed their publicly traded peers. In addition, companies in this group have demonstrated higher margins and more sustained growth."
"We continue to believe that Altairnano's investment in Lithium-Titanate nanotechnology creates a unique commercial battery product, and we are pleased to be recognized for our innovation," stated Terry Copeland, Altairnano President and Chief Executive Officer.
Additional information on the "Best and Brightest" Innovating Companies award and the PATENTVEST evaluation criteria can be found at www.mdb.com
Altair Nanotechnologies Announces Extension of Share SubscriptionAgreement With Canon Investment Holdings
Feb 16, 2011 07:00:57 (ET)
RENO, NV, Feb 16, 2011 (MARKETWIRE via COMTEX) -- Altair Nanotechnologies Inc. (ALTI, Trade ) (the "Company") today announced that the Company and Canon Investment Holdings Limited ("Canon") have entered into a First Amendment to Share Subscription Agreement (the "Amendment") to the Share Subscription Agreement dated September 20, 2010 (the "Agreement") between the Company and Canon. Pursuant to the terms of the Agreement and the Amendment, Canon has agreed to acquire newly issued shares of the Company's common stock resulting in a 51% ownership immediately upon the closing. The Amendment, among other things, extends the closing deadline and the closing date for the proposed acquisition to May 17, 2011.
In addition, the Amendment allows the Company to raise additional capital from third parties prior to May 1, 2011 through issuances of shares of common stock and/or warrants for up to 20% of the Company's outstanding shares of common stock, subject to an aggregate offering cap of US$7,500,000 if any issuance is made at a price (taking into account the implied value of any warrants issued in connection with such issuance) lower than US$1.5528, the per share price at which Canon will be acquiring newly issued shares of the Company's common stock. In addition, if the Company makes any issuance at a price (taking into account the implied value of any warrants issued in connection with such issuance) lower than US$1.5528, Canon will have the ability to terminate the Agreement.
The Amendment further includes provisions deferring the purchase and sale of nLTO under the Conditional Supply and Technology Licensing Agreement entered into by and among the Company, Canon and/or their respective subsidiaries for six months or, if later, until the parties have resolved issues relating to the transfer of technology.
The Company has retained JMP Securities as its investment banker to secure the alternative financing described above.
About Altair Nanotechnologies Inc. Headquartered in Reno, Nev. with manufacturing in Anderson, Ind., Altairnano is a leading provider of fast response battery systems technology. Altairnano's lithium-titanate based battery systems are among the highest performing in the world, and are used primarily to provide regulation and renewable integration in the areas of mass transit and stationary power. For more information, please visit Altairnano at www.altairnano.com .
Forward-Looking Statements This release may contain forward-looking statements as well as historical information. Forward-looking statements, which are included in accordance with the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, may involve risks, uncertainties and other factors that may cause the company's actual results and performance in future periods to be materially different from any future results or performance suggested by the forward-looking statements in this release. These risks and uncertainties include, without limitation, the risk that the remaining differences between the parties cannot be resolved or that various other conditions to the closing of the Canon transaction may not be satisfied and, as a result, the transaction may not close; and that if it does close significant cultural and business differences may make it difficult to realize the anticipated benefits. In addition, other risks are identified in the Company's most recent Annual Report on Form 10-K and Form 10-Q, as filed with the SEC. Such forward-looking statements speak only as of the date of this release. The Company expressly disclaims any obligation to update or revise any forward-looking statements found herein to reflect any changes in company expectations or results or any change in events
close to 7 cents on higher than average volume. looks promising
these are the guys we need to contact bob
http://blogs.orlandosentinel.com/entertainment_movies_blog/2010/03/gilligans-island-the-movie.html
-- 01/31/11 -- Altair Nanotechnologies, Inc. (NASDAQ: ALTI) today announced that on January 28, 2011, it was notified by the Committee on Foreign Investment in the United States ("CFIUS"), that CFIUS had concluded its review and identified no unresolved national security concerns with respect to the investment in the Company by Canon Investment Holdings Limited ("Canon") pursuant to the Share Subscription Agreement, dated September 20, 2010 between Canon and the Company. As a result CFIUS takes no adverse action with respect to the Canon transaction and will advise the relevant members of Congress and the congressional committees accordingly.
The positive conclusion of this CFIUS review was the last remaining major obstacle to the closing of the Canon investment. Company shareholders previously approved the transaction at a special shareholder meeting held on December 27, 2010. The Company anticipates wrapping up the final details during the week of February 6, 2011.
The CFIUS review process was initiated by the Company and Canon jointly filing a voluntary notice on November 23, 2010 requesting review of the proposed transaction. Under the governing regulations, CFIUS had a period of 30 days to review the notification and could, at the end of that period, initiate a 45-day investigation of the transaction. On December 27, 2010, the Company received written notification from CFIUS that it intended to commence such an investigation. The 45-day period was to expire on February 10, 2011, but CFIUS was able to conclude their investigation sooner.
"We are extremely pleased that this final hurdle has been cleared and we can now move forward expeditiously with the close and begin to realize the benefits of the Canon investment and relationship," stated Terry Copeland, Altairnano President and CEO. "We look forward to a bright future with tremendous opportunity."
no word on what this means in terms of dollars, but it does sound promising
alti has a new symbol that goes with the reorg associated with the reserse stock split
we are looking at two different things one is
The mid-month short interest report is based on short positions held by members on the settlement date of the 15th of each month. If the 15th falls on a weekend or another non-settlement date, the designated settlement date will be the previous business day on which transactions settled.
the other is
The Daily Short Sale Volume File will provide daily access to the aggregate volume of
short sales in NMS Stocks and OTC Equity Securities reported to a consolidated tape and
traded over-the-counter during regular trading hours on each trading day. FINRA will post the Daily Short Sale Volume File within a reasonable amount of time after the end
of regular trading hours on each trading day.
where are you getting these numbers from?
here is a passage from FINRA. org with the applicable link. It appears to me that they are actual short sales applicable to that particular date.
"Daily Short Sale Volume File
The Daily Short Sale Volume File will provide daily access to the aggregate volume of
short sales in NMS Stocks and OTC Equity Securities reported to a consolidated tape and
traded over-the-counter during regular trading hours on each trading day. FINRA will
post the Daily Short Sale Volume File within a reasonable amount of time after the end
of regular trading hours on each trading day. Specifically, the Daily Short Sale Volume
File will include the following:
trade date;
trading symbol;
aggregate reported share volume of executed short sale trades during regular
trading hours;
aggregate reported share volume of all executed trades during regular trading
hours; and
market identifier."
http://www.finra.org/web/groups/industry/@ip/@reg/@notice/documents/notices/p120044.pdf
I actually called FINRA and asked about the numbers. They are not Failure to deliver
How do you know they are failures to deliver. There is nothing indicating that on the web site
who are they put out by.
over 50% of the sales yesterday were short sales. Possible squeeze.
20101130|VCSY|304912|510321|O
http://regsho.finra.org/FORFshvol20101130.txt
Actually closer to 60%
barcharts has reduced this to a hold
565,000 short sales or 16% out of 3,585,027. So most are just flat out sells. Not shorts, not naked but sells
20101123|BUGS|565000|3585027|O
http://regsho.finra.org/FORFshvol20101123.txt
we will see what the numbers say. there are no indications of failure to deliver. No reason to believe these are naked shorts (But they may be). It may be that when we hit a certain range the short sellers jump in and drive the price down.
if there is no reason to go up, it wil be driven down, this is a game that may go on indefinitely
barcharts.com BUGS SELL
http://www.barchart.com/quotes/stocks/BUGS
Barcharts.com ATPT SELL
http://www.barchart.com/quotes/stocks/ATPT
sorry wrong board